ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Shanghai Hansoh Biomedical Co., Ltd
- Target Recruit Count
- 177
- Registration Number
- NCT05276609
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of HS-20089 in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: HS-20089 (Phase Ia：Dose escalation )
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Shanghai Hansoh Biomedical Co., Ltd
- Target Recruit Count
- 177
- Registration Number
- NCT05263479
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Comparing of the Pharmacokinetic, Safety and Immunogenicity of HS-20090-2 Injection and Prolia® in Healthy Adults
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Shanghai Hansoh Biomedical Co., Ltd
- Target Recruit Count
- 174
- Registration Number
- NCT04940845
- Locations
- 🇨🇳
Huazhong University of Science and Technoogy, Wuhan, Hubei, China
© Copyright 2025. All Rights Reserved by MedPath